Drawing based on the label description. No photo yet.
IMPRINT LL pill
Pill with imprint IMPRINT LL is pink, round, 8 mm and has been identified as Trametinib 2 mg. It is used for lung cancer and melanoma. It is supplied by Novartis Pharmaceuticals Corporation.
Trametinib 2 mg
- Imprint
- IMPRINT LL
- Strength
- 2 mg
- Used for
- Lung cancer and melanoma
- Color
- Pink
- Shape
- Round
- Size
- 8 mm
- Score
- No score line
- Form
- Tablet, film coated
- Manufacturer
- Novartis Pharmaceuticals Corporation
- Drug class
- Cancer medicine (kinase inhibitor)
- NDC
- 0078-1112, 0078-1112-15, 0078-1112-94
Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .
Report a mistake
What is Trametinib used for?
Trametinib is used for lung cancer and melanoma.
- Medicine type
- Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label
BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma
MEKINIST® is indicated, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma
MEKINIST is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.
BRAF V600E Mutation-Positive Metastatic NSCLC
MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.
BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer
MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.
BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
MEKINIST is indicated, in combination with dabrafenib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
BRAF V600E Mutation-Positive Low-Grade Glioma
MEKINIST is indicated, in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy.
Limitations of Use
MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.
From the FDA-approved label on DailyMed (published May 20, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- Your pill shows IMPRINT LL. The parts can be split between the two sides, so turn the pill over and check both.
- It is pink, round, 8 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Sold under the brand name Mekinist.
Ingredients
Active: Trametinib Dimethyl Sulfoxide
Inactive: Silicon Dioxide, Croscarmellose Sodium, Hypromelloses, Magnesium Stearate, Mannitol, Microcrystalline Cellulose, Sodium Lauryl Sulfate, Ferric Oxide Red, Polyethylene Glycol, Polysorbate 80, Titanium Dioxide
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
Y04
Venlafaxine Hydrochloride 75 mg
Pink, round, 9 mm
Used for depression and anxiety
-
Y03
Venlafaxine Hydrochloride 50 mg
Pink, round, 8 mm
Used for depression and anxiety
-
Y02
Venlafaxine Hydrochloride 37.5 mg
Pink, round, 7 mm
Used for depression and anxiety
-
498
Zolmitriptan 5 mg
Pink, round, 9 mm
Used for migraine
-
G 52
Solifenacin Succinate 10 mg
Pink, round, 8 mm
Used for overactive bladder
-
AN 83
Paliperidone 9 mg
Pink, round, 8 mm
Used for depression and bipolar disorder
Other Trametinib pills
- IMPRINT TT Trametinib .5 mg Yellow, oval, 9 mm Used for lung cancer and melanoma
- No picture yet DIN 02409623 Trametinib 0.5 mg Mekinist, Tablet, sold in Canada Used for lung cancer and melanoma
- No picture yet DIN 02409658 Trametinib 2 mg Mekinist, Tablet, sold in Canada Used for lung cancer and melanoma